Meier P, Timmis A. Almanac 2012: interventional cardiology.
Anadolu Kardiyol Derg 2012;13:91-101. [PubMed]
 Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-6. [Crossref]
 European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al.
Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429. [PubMed]
 Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008;6:1500-6. [Crossref] [Web of Science] [PubMed]
 Garcia-Fernandez MA, Perez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 2003;42:1253-8. [Crossref]
 MEMBERS WC, Bonow RO, Carabello BA, et al. 2008
Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998
Guidelines for the Management of PatientsWith Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
 Munkholm-Larsen S, Cao C, Yan TD, et al. Percutaneous atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review. Heart 2012;98:900-7. [Crossref]
 Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42. [Web of Science]
 Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013;127:720-9. [Crossref]
 Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123:417-24.
 Massumi A, Chelu MG, Nazeri A, et al. Initial experience with a novel percutaneous left atrial appendage exclusion device in patients with atrial fibrillation, increased stroke risk, and contraindications to anticoagulation. Am J Cardiol 2013;111:869-73. [Crossref] [PubMed]
 Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol 2012;59:923-9. [Web of Science]
 Bass JL. Transcatheter occlusion of the left atrial appendage - experimental testing of a new Amplatzer device. [PubMed]
Catheter Cardiovasc Interv 2010;76:181-5. [PubMed]
 Fox BD, Kahn SR, Langleben D, et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012;345:e7498.
 Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
Eur Heart J 2012;33:2719-47. [PubMed]
 Iung B, Vahanian A. Degenerative calcific aortic stenosis: a natural history. Heart 2012;98:iv7-13. [Web of Science]
 Delgado V, Kapadia S, Marsan NA, et al. Multimodality imaging before, during, and after percutaneous mitral valve repair. Heart 2011;97:1704-14. [Crossref]
 Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST phase I clinical trial. J Am Coll Cardiol 2005;46:2134-40. [Crossref] [PubMed]
 Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395-406.
 Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) high risk study. J Am Coll Cardiol 2012;59:130-9. [Web of Science]
 Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009;54:686-94. [PubMed] [Web of Science] [Crossref]
 Sürder D, Pedrazzini G, Gaemperli O, et al. Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry. [PubMed]
Heart 2013;99:1034-40. [PubMed]
 Kar S, Rinaldi M, Lim DS, et al. EVEREST II REALISM: a continued access study to evaluate the safety and effectiveness of the MitraClip device: demographics and procedural outcomes. Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions; Baltimore, 2011.
 Rinaldi MJ, Kar S, Lim DS, et al. EVEREST II REALISM: a continued access study to evaluate the safety and effectiveness of the MitraClip device: analysis of a 6 month patient cohort. Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions; Baltimore, 2011.
 Sarkar K, Ussia GP, Cammalleri V, et al. Quality of life of high risk patients following percutaneous mitral valve repair with the MitraClip system. Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions; Baltimore, 2011.
 Gaemperli O, Moccetti M, Surder D, et al. Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 2012;98:126-32. [Web of Science] [Crossref] [PubMed]
 Samad Z, Kaul P, Shaw LK, et al. Impact of early surgery on survival of patients with severe mitral regurgitation.
Heart 2011;97:221-4. [PubMed]
 Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11.
 Rosenhek R. Almanac 2011: valvular heart disease. The national society journals present selected research that has driven recent advances in clinical cardiology. Heart 2011;97:2007-17. [Crossref]
 Sinning J-M, Werner N, Nickenig G, et al. Transcatheter aortic valve implantation: the evidence. Heart 2012;98:iv65-72.
 Watt M, Mealing S, Eaton J, et al. Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart 2012;98:370-6. [Web of Science] [Crossref] [PubMed]
Seminars in Cardiovascular Medicine
The Journal of Lithuanian Heart Association
1 Issue per year
Almanac 2013: novel non-coronary cardiac interventions
- Division of Cardiology, Yale Medical School, New Haven, Connecticut, USA
- Division of Cardiology, Rigshopitalet University Hospital Copenhagen, Copenhagen, Denmark
Recent innovations in interventional cardiology have dramatically expanded the therapeutic options for patients with cardiac conditions. Interventional cardiology is no longer limited to the treatment of coronary artery disease but allows also treatment of valvular disease, stroke prevention, hypertension, etc. One of the most important new treatment options is the percutaneous treatment for aortic valve stenosis (transcatheter aortic valve implantation), since aortic valve disease is a rather common problem in elderly patients, with many of them at high risk for surgery. Similarly, mitral regurgitation is often associated with comorbidities which make surgery high risk. The MitraClip is a promising percutaneous alternative to surgical valve repair or replacement. Other procedures discussed in this review are the percutaneous left atrial appendage closure as a non-pharmacologic therapy to prevent strokes, and renal denervation for resistant hypertension. This review explains the basic principles of these procedures, the most important clinical evidence, and also provides additional recent clinical data on each of these them.